

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptasel1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 4 APR 07 STN is raising the limits on saved answers
NEWS 5 APR 24 CA/CAPplus now has more comprehensive patent assignee
information
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent
assignment/reassignment information
NEWS 7 APR 28 CAS patent authority coverage expanded
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9 APR 28 Limits doubled for structure searching in CAS
REGISTRY
NEWS 10 MAY 08 STN Express, Version 8.4, now available
NEWS 11 MAY 11 STN on the Web enhanced
NEWS 12 MAY 11 BEILSTEIN substance information now available on
STN Easy
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased
limits for exact sequence match searches and
introduction of free HIT display format
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal
status data
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in
records back to 1992
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching
enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:23:39 ON 18 JUN 2009

```
=> fil reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          0.22      0.22
```

FILE 'REGISTRY' ENTERED AT 09:23:52 ON 18 JUN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUN 2009 HIGHEST RN 1158716-03-0
 DICTIONARY FILE UPDATES: 16 JUN 2009 HIGHEST RN 1158716-03-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\STNEXP\Queries\10568486.str
```




```
chain nodes :
2 3 4 5 6 7 16 23
ring nodes :
1 8 9 10 11 12 13 14 15 17 18 19 20 21 22
chain bonds :
1-2 2-3 3-4 4-5 5-6 6-7 6-23 7-8 14-16 16-17
ring bonds :
1-13 1-15 8-9 8-12 9-10 10-11 11-12 13-14 14-15 17-18 17-22 18-19 19-20
20-21 21-22
```

exact/norm bonds :
 1-2 1-13 1-15 4-5 5-6 6-7 6-23 7-8 8-9 8-12 9-10 10-11 11-12 13-14
 14-15 14-16 16-17
 exact bonds :
 2-3 3-4
 normalized bonds :
 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
 1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:Atom 9:Atom
 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom
 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
 SAMPLE SEARCH INITIATED 09:24:09 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 09:24:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L3 5 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 09:24:14 ON 18 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2009 VOL 150 ISS 25
FILE LAST UPDATED: 17 Jun 2009 (20090617/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3
L4 1 L3

=> d ibib abs hitstr tot


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 2005:260019 CAPLUS
DOCUMENT NUMBER: 142:336234
TITLE: Preparation of 1,3-disubstituted azetidine
derivatives
for use as CCR-3 receptor antagonists in the
treatment
of inflammatory and allergic diseases
INVENTOR(S): Le Grand, Darren Mark
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026113	A1	20050324	WO 2004-EP10260	20040914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004272275	A1	20050324	AU 2004-272275	20040914
AU 2004272275	B2	20090226		
CA 2534550	A1	20050324	CA 2004-2534550	20040914
EP 1663966	A1	20060607	EP 2004-765174	20040914
EP 1663966	B1	20070620		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1849302	A	20061018	CN 2004-80026204	20040914
BR 2004014416	A	20061114	BR 2004-14416	20040914
JP 2007505080	T	20070308	JP 2006-525789	20040914
AT 365155	T	20070715	AT 2004-765174	20040914
ES 2286664	T3	20071201	ES 2004-765174	20040914
IN 2006CN00883	A	20070608	IN 2006-CN883	20060313
MX 2006002870	A	20060605	MX 2006-2870	20060314
US 20070043013	A1	20070222	US 2006-568486	20060811
PRIORITY APPLN. INFO.:			GB 2003-21599	A 20030915
			GB 2003-21600	A 20030915
OTHER SOURCE(S):	CASREACT 142:336234; MARPAT 142:336234		WO 2004-EP10260	W 20040914
GI				


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



Absolute stereochemistry.





Absolute stereochemistry.



Absolute stereochemistry.


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




AB Comps. of formula I and II [Ar = Ph optionally substituted by one or more substituents selected from halo, C1-C8-alkyl, cyano, nitro; X1 = S, S(O), S(O)2; X2 = C(O), O, CH2, S, S(O), S(O)2; m = 1, 2, 3, 4; R1 = H, C1-C8-alkyl optionally substituted; Q = C(Rb)(Rc) where Rb and Rc are independently C1-C8-alkyl or Rb and Rc together form a C3-C10-cycloalkyl; Y = O, S; R2 = H, C1-C8-alkyl, C3-C10-cycloalkyl; R3 = C1-C8-alkyl substituted by Ph, phenoxy, acyloxy, naphthyl, or R3 is C3-C10-cycloalkyl optionally having a benzo group, a heterocyclic group] were prepared and are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. E.g., 1-benzhydryl-3-(4-chlorophenylsulfanyl)azetidine was oxidized with MCPBA, and treated with 1-chloroethoxycarbonyl chloride to give 3-(4-chlorobenzenesulfinyl)azetidine. Reaction of the latter with [(S)-1-(tert-butyl)diphenylsilyl]azetidine-3-iodopropylcarbamate acid tert-Bu ester gave [(S)-1-(tert-butyl)diphenylsilyl]azetidine-3-[3-(4-chlorophenylsulfanyl)azetidin-1-yl]propylcarbamate acid tert-Bu ester. The latter was desilylated, then treated with TFA to give (S)-2-amino-4-[3-(4-chlorobenzenesulfinyl)azetidin-1-yl]butan-1-ol. Reaction of the latter with 3,5-dimethoxyphenyl isocyanate resulted in 1-[(S)-3-[3-(4-chlorobenzenesulfinyl)azetidin-1-yl]-1-hydroxymethylpropyl]-3-(3,5-dimethoxyphenyl)urea.
IT 848642-40-0P 848642-46-6P 848642-52-4P
848642-57-9P 848642-63-7P
R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-disubstituted azetidine derivs. for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases)
RN 848642-40-0 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.14	192.24

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.82	-0.82

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 09:24:27 ON 18 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.



STRUCTURE FILE UPDATES: 16 JUN 2009 HIGHEST RN 1158716-03-0
DICTIONARY FILE UPDATES: 16 JUN 2009 HIGHEST RN 1158716-03-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of




1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:Atom 9:Atom
10:Atom 11:CLASS 12:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



=> fil caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
186.84	379.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.82

FILE 'CAPLUS' ENTERED AT 09:26:18 ON 18 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2009 VOL 150 ISS 25
FILE LASTUPDATED: 17 Jun 2009 (20090617/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1016895 CAPLUS
DOCUMENT NUMBER: 143:415586
TITLE: G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation
AUTHOR(S): Rolland, Catherine; Goralbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic
CORPORATE SOURCE: Cerep, Rueil-Malmaison, 92500, Fr.
SOURCE: Journal of Medicinal Chemistry (2005), 48 (21), 6563-6574
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A QSAR model accounting for "average" G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of reference compds. at 10 μ M. A 5.5-fold enrichment in positives was observed when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also observed for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.

IT 868056-90-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)
RN 868056-90-0 CAPLUS
CN Urea,
N-[3-[[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-[1-(1,1-dimethylethyl)-3-ethyl-1H-pyrazol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:983973 CAPLUS
DOCUMENT NUMBER: 143:286418
TITLE: Preparation of hydroxy containing isothiazole based protein kinase inhibitors
INVENTOR(S): Liang, Congxin
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005081997	A2	20050909	WO 2005-US5859	20050222
WO 2005081997	A3	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-546538P P 20040220

OTHER SOURCE(S): CASREACT 143:286418; MARPAT 143:286418
GI




AB Title compds. I [X = O, S; R1 = alkyl, cycloalkyl, substituted arylalkyl, etc.; R2 and R3 independently = H or alkyl; R4 = H, OH, or alkyl; R5 = OH,

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.


FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
alkoxy, cycloalkoxy, etc.; n and m independently = 0-3; p = 1-3], as well as their pharmaceutically acceptable salts, are prepd. and disclosed as having enhanced and unexpected drug properties as inhibitors of protein kinases. Thus, e.g., the prepn. of II was demonstrated in a multistep synthesis. In VEGFR assays, I exhibited IC50 values between 1-5,000 nM. As protein kinase inhibitors, I should prove useful in treating disorders related to abnormal protein kinase activities such as cancer.


IT 864288-45-9P 864288-46-OP 864288-62-OP
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of isothiazole based protein kinase inhibitors)
RN 864288-45-9 CAPLUS
CN 4-Isouthiazolecarboxamide,
3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[2-hydroxy-3-(3-hydroxy-1-azetidiny)-3-oxopropyl]amino]carbonyl]amino]- (CA INDEX NAME)



RN 864288-46-0 CAPLUS
CN 4-Isouthiazolecarboxamide,
3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[[2-hydroxy-3-(3-methoxy-1-azetidiny)-3-oxopropyl]amino]carbonyl]amino]- (CA INDEX NAME)



RN 864288-62-0 CAPLUS
 CN 3-Azetidinecarboxylic acid,
 1-[3-[[[4-(aminocarbonyl)-3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-isothiazolyl]amino]carbonyl]amino]-2-hydroxy-1-oxopropyl]- (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2005:260019 CAPLUS
 DOCUMENT NUMBER: 142:336234
 TITLE: Preparation of 1,3-disubstituted azetidine derivatives
 for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases
 INVENTOR(S): Le Grand, Darren Mark
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026113	A1	20050324	WO 2004-EP10260	20040914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004272275	A1	20050324	AU 2004-272275	20040914
AU 2004272275	B2	20090226		
CA 2534550	A1	20050324	CA 2004-2534550	20040914
EP 1663966	A1	20060607	EP 2004-765174	20040914
EP 1663966	B1	20070620		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1849302	A	20061018	CN 2004-80026204	20040914
BR 2004014416	A	20061114	BR 2004-14416	20040914
JP 2007505080	T	20070308	JP 2006-525789	20040914
AT 365155	T	20070715	AT 2004-765174	20040914
ES 2286664	T3	20071201	ES 2004-765174	20040914
IN 2006CN00883	A	20070608	IN 2006-CN883	20060313
MX 2006002870	A	20060605	MX 2006-2870	20060314
US 20070043013	A1	20070222	US 2006-568486	20060811
PRIORITY APPLN. INFO.:			GB 2003-21599	A 20030915
			GB 2003-21600	A 20030915
			WO 2004-EP10260	W 20040914

OTHER SOURCE(S): CASREACT 142:336234; MARPAT 142:336234
 GI




AB Comps. of formula I and II [Ar = Ph optionally substituted by one or more substituents selected from halo, C1-C8-alkyl, cyano, nitro; X1 = S, S(O), S(O)2; X2 = C(O), O, CH2, S, S(O), S(O)2; m = 1, 2, 3, 4; R1 = H, C1-C8-alkyl optionally substituted; Q = C(Rb)(Rc) where Rb and Rc are independently C1-C8-alkyl or Rb and Rc together form a C3-C10-cycloalkyl; Y = O, S; R2 = H, C1-C8-alkyl, C3-C10-cycloalkyl; R3 = C1-C8-alkyl substituted by Ph, phenoxy, acyloxy, naphthyl, or R3 is C3-C10-cycloalkyl optionally having a benzo group, a heterocyclic group] were prepared and are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. E.g., 1-benzhydryl-3-(4-chlorophenylsulfanyl)azetidine was oxidized with MCPBA, and treated with 1-chloroethoxycarbonyl chloride to give 3-(4-chlorobenzesulfanyl)azetidine. Reaction of the latter with [(S)-1-(tert-butyl)diphenylsilylanyloxymethyl]-3-[3-(4-chlorophenylsulfanyl)azetidin-1-yl]propyl]carbamate acid tert-Bu ester gave [(S)-1-(tert-butyl)diphenylsilylanyloxymethyl]-3-[3-(4-chlorophenylsulfanyl)azetidin-1-yl]propyl]carbamate acid tert-Bu ester. The latter was desilylated, then treated with TFA to give (S)-2-amino-4-[3-(4-chlorobenzesulfanyl)azetidin-1-yl]butan-1-ol. Reaction of the latter with 3,5-dimethoxyphenyl isocyanate resulted in

1-[(S)-3-[3-(4-chlorobenzesulfanyl)azetidin-1-yl]-1-hydroxymethylpropyl]-3-(3,5-dimethoxyphenyl)urea.
 IT 848642-39-7P 848642-40-OP 848642-41-1P
 848642-42-2P 848642-43-3P 848642-44-4P
 848642-45-5P 848642-46-6P 848642-47-7P
 848642-48-8P 848642-49-9P 848642-50-2P
 848642-51-3P 848642-52-4P 848642-53-5P
 848642-54-6P 848642-55-7P 848642-56-8P
 848642-57-9P 848642-58-OP 848642-59-1P
 848642-60-4P 848642-61-5P 848642-62-6P
 848642-63-7P 848642-64-8P 848642-65-9P
 848642-66-OP 848642-67-1P 848642-68-2P
 848643-32-3P 848643-33-4P 848643-34-5P
 848643-35-6P 848643-36-7P 848643-37-8P
 848643-38-9P 848643-39-OP 848643-40-3P
 848643-41-4P 848643-45-8P 848643-46-9P
 848643-47-OP 848643-48-1P 848643-49-2P
 848643-50-5P 848643-51-6P 848643-52-7P
 848643-53-8P 848643-54-9P 848643-56-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
 (prepn. of 1,3-disubstituted azetidine derivs. for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases)


RN 848642-39-7 CAPLUS
 CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-40-0 CAPLUS
 CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-41-1 CAPLUS
 CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-42-2 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848642-43-3 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-3-isoxazolyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 848642-44-4 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 848642-48-8 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-49-9 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(5-ethyl-3-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-50-2 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-45-5 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-46-6 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-47-7 CAPLUS
CN Urea, N-[(1R)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848642-51-3 CAPLUS
CN Urea, N-[(1R)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-52-4 CAPLUS
CN Urea, N-[(1R)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-53-5 CAPLUS
CN Urea, N-[(1R)-3-[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-(methoxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-54-6 CAPLUS
CN Urea, N-[(1R)-3-[[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-methylpropyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-55-7 CAPLUS
CN Urea, N-[(1R)-3-[[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-methylpropyl]-N'-(5-ethyl-3-isoxazolyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-56-8 CAPLUS
CN Urea, N-[(1R)-3-[[3-[(4-chlorophenyl)sulfinyl]-1-azetidiny]-1-methylpropyl]-N'-(3-ethyl-5-isoxazolyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-60-4 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-61-5 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-3-isoxazolyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-62-6 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-57-9 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-58-0 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-59-1 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)thio]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-63-7 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)]- (CA INDEX NAME)

Absolute stereochemistry.



RN 848642-64-8 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 848642-65-9 CAPLUS
CN Urea, N-[(1S)-3-[[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)]- (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 848642-66-0 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-67-1 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 848642-68-2 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)sulfonyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-35-6 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclobutyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-36-7 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)


L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.



RN 848643-32-3 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 848643-33-4 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-34-5 CAPLUS


L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 848643-37-8 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-3-isoxazolyl)- (CA INDEX NAME)




RN 848643-38-9 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)



L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 848643-39-0 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 848643-40-3 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-41-4 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 848643-45-8 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclobutyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-46-9 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)


L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 848643-47-0 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-3-isoxazolyl)- (CA INDEX NAME)




RN 848643-48-1 CAPLUS
 CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)




L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 848643-49-2 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 848643-50-5 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 848643-51-6 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-52-7 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-cyclobutyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 848643-53-8 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)


L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



RN 848643-54-9 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(5-ethyl-5-isoxazolyl)- (CA INDEX NAME)




RN 848643-56-1 CAPLUS
 CN Urea, N-[3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1,1-dimethylpropyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)



L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:757517 CAPLUS
 DOCUMENT NUMBER: 139:276805
 TITLE: Preparation of azetidine derivatives as CCR-3
 receptor
 INVENTOR(S): antagonists
 Le Grand, Darren Mark; McCarthy, Clive; Walker, Clive
 Victor; Woods, John James
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077907	A1	20030925	WO 2003-EP2715	20030314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LI, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2479266	A1	20030925	CA 2003-2479266	20030314
AU 2003227072	A1	20030929	AU 2003-227072	20030314
AU 2003227072	B2	20060810		
EP 1487435	A1	20041222	EP 2003-744367	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008419	A	20050118	BR 2003-8419	20030314
CN 1638761	A	20050713	CN 2003-805648	20030314
JP 2005526773	T	20050908	JP 2003-575960	20030314
NZ 535082	A	20060831	NZ 2003-535082	20030314
RU 2314292	C2	20080110	RU 2004-130487	20030314
US 20050222118	A1	20051006	US 2004-507139	20040909
US 7288537	B2	20071030		
IN 2004CN02026	A	20060224	IN 2004-CN2026	20040910
MX 2004009057	A	20050125	MX 2004-9057	20040915
NO 2004004373	A	20041014	NO 2004-4373	20041014
ZA 2004006752	A	20060531	ZA 2004-6752	20060322
JP 2009102325	A	20090514	JP 2008-302924	20081127
PRIORITY APPLN. INFO.:				
			GB 2002-6218	A 20020315
			GB 2002-29627	A 20021219
			JP 2003-575960	A3 20030314
			WO 2003-EP2715	W 20030314

OTHER SOURCE(S): MARPAT 139:276805
 GI



AB The title compds. [I; Ar = (un)substituted Ph; R1 = H, alkyl optionally substituted by OH, alkoxy, acyloxy, halo, CO₂H, etc.; R2 = H, alkyl or cycloalkyl, and R3 = alkyl substituted by Ph, OPh, acyloxy or naphthyl, or R3 = cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5-11 ring atoms of which 1-4 are heteroatoms, (un)substituted Ph or naphthyl, or R2 and R3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5-10 ring atoms of which 1-3 are heteroatoms; X = CO, O, CH₂, CH(OH); Y = O, S; m = 1-4; and n, p and q = 0, 1 (n+p+q = 1, 2; n+q = 1; p+q = 1; and when n = 0, p = 0)], useful for treating conditions mediated by CCR3, were prepared

Thus, reacting (S)-2-amino-4-[3-(4-chlorophenoxy)azetidin-1-yl]butan-1-ol with 3,5-dimethoxyphenyl isocyanate in CH₂Cl₂ afforded the urea (S)-II which showed IC₅₀ of 0.007 μM against CCR-3 binding. The exemplified compds. I generally have IC₅₀ values below 1 μM in CCR-3 binding assay. Pharmaceutical compds. that contain the compds. I and processes for preparing the compds. are also described.

IT 606127-51-9P 606127-52-0P 606127-53-1P
606127-54-2P 606127-56-4P 606127-58-6P
606127-59-7P 606127-61-1P 606127-62-2P
606127-64-4P 606127-66-6P 606127-68-8P
606127-70-2P 606127-72-4P 606127-73-5P
606127-74-6P 606127-76-8P 606127-77-9P
606127-78-0P 606127-79-1P 606127-80-4P
606127-81-5P 606127-82-6P 606127-83-7P
606127-84-8P 606127-85-9P 606127-86-0P
606127-87-1P 606127-88-2P 606127-89-3P
606127-90-6P 606127-91-7P 606127-92-8P
606127-93-9P 606127-94-0P 606127-96-2P
606128-06-7P 606128-07-8P 606128-08-9P
606128-09-0P 606128-10-3P 606128-11-4P
606128-12-5P 606128-13-6P 606128-14-7P
606128-15-8P 606128-16-9P 606128-18-1P
606128-19-2P 606128-20-5P 606128-21-6P
606128-22-7P 606128-23-8P 606128-24-9P
606128-25-0P 606128-26-1P 606128-27-2P
606128-28-3P 606128-29-4P 606128-31-8P


606128-33-0P 606128-35-2P 606128-38-5P
606128-40-9P 606128-42-1P 606128-44-3P
606128-46-5P 606128-48-7P 606128-50-1P
606128-52-3P 606128-54-5P 606128-56-7P
606128-58-9P 606128-60-3P 606128-62-5P
606128-64-7P 606128-66-9P 606128-68-1P
606128-70-5P 606128-72-7P 606128-74-9P
606128-76-1P 606128-78-3P 606128-80-7P
606128-82-9P 606128-84-1P 606128-86-3P
606128-88-5P 606128-90-9P 606128-92-1P
606128-94-3P 606128-96-5P 606128-98-7P
606129-00-4P 606129-02-6P 606129-04-8P
606129-06-0P 606129-08-2P 606129-10-6P
606129-13-9P 606129-17-3P 606129-18-4P
606129-19-5P 606129-20-8P 606129-21-9P
606129-22-0P 606129-23-1P 606129-24-2P
606129-25-3P 606129-26-4P 606129-27-5P
606129-28-6P 606129-29-7P 606129-30-0P
606129-31-1P 606129-32-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azetidine derivs. as CCR-3 receptor antagonists)


RN 606127-51-9 CAPLUS

CN Urea, N-(3,5-dimethoxyphenyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidinyl]propyl]- (CA INDEX NAME)




RN 606127-52-0 CAPLUS

CN Urea, N-(3,5-dimethoxyphenyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)




RN 606127-53-1 CAPLUS

CN Urea, N-[3-[3-(4-fluorophenoxy)-1-azetidinyl]propyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)



RN 606127-54-2 CAPLUS

CN Urea, N-(3,4-difluorophenyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidinyl]propyl]- (CA INDEX NAME)




RN 606127-56-4 CAPLUS

CN Urea, N-[3-[3-(4-fluorophenoxy)-1-azetidinyl]propyl]-N'-[1-(1-naphthalenyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-55-3
CMF C25 H28 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 606127-58-6 CAPLUS

CN Urea, N-[3-[3-(4-fluorophenoxy)-1-azetidinyl]propyl]-N'-tricyclo[3.3.1.1^{3,7}]dec-2-yl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-57-5
CMF C23 H32 F N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 606127-59-7 CAPLUS

CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 606127-61-1 CAPLUS
CN Urea, N-(3-ethylphenyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidiny]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-60-0
CMF C21 H26 F N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 606127-62-2 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,4-difluorophenyl)- (CA INDEX NAME)



RN 606127-64-4 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 606127-63-3
CMF C21 H26 Cl N3 O4

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(2,3-dichlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-67-7
CMF C20 H22 Cl3 N3 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 606127-70-2 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(4-fluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 606127-69-9
CMF C20 H23 Cl F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 606127-66-6 CAPLUS
CN Urea, N-(2,3-dimethylphenyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidiny]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-65-5
CMF C21 H26 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 606127-68-8 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,4-difluorophenyl)- (CA INDEX NAME)


L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 606127-72-4 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2-chlorophenyl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-71-3
CMF C21 H25 Cl2 N3 O3




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 606127-73-5 CAPLUS
CN Urea, N-(3,5-dimethoxyphenyl)-N'-[3-[3-(4-fluorobenzoyl)-1-azetidiny]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)




RN 606127-74-6 CAPLUS
CN Urea,
N-[3-[3-(3,4-dichlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 606127-76-8 CAPLUS
CN Urea, N-(2,3-dihydro-5-benzofuranyl)-N'-[3-[3-(4-fluorophenoxy)-1-azetidiny]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 606127-75-7
CMP C21 H24 F N3 O3




CM 2


CRN 76-05-1
CMP C2 H F3 O2




RN 606127-77-9 CAPLUS
CN Urea,
N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]propyl]-N'-
(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 606127-82-6 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(2,3-dihydro-1H-inden-2-yl)- (CA INDEX NAME)




RN 606127-83-7 CAPLUS
CN Urea,
N-[3-[3-(4-fluorophenoxy)-1-azetidiny]propyl]-N'-
(3-hydroxyphenyl)- (CA INDEX NAME)




RN 606127-84-8 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 606127-78-0 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(3-chlorophenyl)- (CA INDEX NAME)




RN 606127-79-1 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(3-ethylphenyl)- (CA INDEX NAME)




RN 606127-80-4 CAPLUS
CN Urea, N-(3-acetylphenyl)-N'-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-
(hydroxymethyl)propyl]- (CA INDEX NAME)




RN 606127-81-5 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(2,3-dimethylphenyl)- (CA INDEX NAME)




RN 606127-85-9 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(4-methylphenyl)- (CA INDEX NAME)




RN 606127-86-0 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(4-methoxyphenyl)- (CA INDEX NAME)




RN 606127-87-1 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(2,4-difluorophenyl)- (CA INDEX NAME)




RN 606127-88-2 CAPLUS
CN Urea,
N-[3-[3-(4-chlorophenoxy)-1-azetidiny]propyl]-N'-
(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 606127-89-3 CAPLUS
CN Urea, N-[3-[3-(4-chlorobenzoyl)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 606127-90-6 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,4-dimethylphenyl)- (CA INDEX NAME)




RN 606127-91-7 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-difluorophenyl)- (CA INDEX NAME)




RN 606127-92-8 CAPLUS

Absolute stereochemistry.




RN 606128-07-8 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 606128-08-9 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 606128-09-0 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 606127-93-9 CAPLUS
CN Urea, N-[3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)



RN 606127-94-0 CAPLUS
CN Urea, N'-[3-[3-(4-fluorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 606127-96-2 CAPLUS
CN Urea, N-[3-[3-(4-fluorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)




RN 606128-06-7 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-10-3 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-11-4 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-12-5 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-13-6 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-14-7 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-15-8 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-19-2 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-20-5 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-21-6 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-16-9 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-18-1 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-(1-methylethyl)-1,2,4-thiadiazol-5-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 606128-17-0
CMP C19 H26 Cl N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 606128-22-7 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-(1,1-dimethylethyl)-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-23-8 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-24-9 CAPLUS
CN Urea, N-[(1S)-3-[3-[(4-chlorophenyl)methyl]-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-25-0 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-(1-methylethyl)-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-26-1 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-methyl-1,2,4-thiadiazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-27-2 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.


RN 606128-33-0 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorobenzoyl)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-35-2 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.





RN 606128-38-5 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-5-isoxazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 606128-37-4
CMP C19 H25 Cl N4 O4

Absolute stereochemistry.




RN 606128-28-3 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(2-methyl-2H-tetrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-29-4 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-31-8 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(2-ethyl-2H-tetrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 606128-40-9 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-42-1 CAPLUS
CN Urea, N-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-44-3 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(2-methyl-5-thiazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-46-5 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-48-7 CAPLUS
CN Benzanide, 3-[[[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]amino]carbonylamino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-50-1 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-ethynylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-58-9 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2-cyano-4,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-60-3 CAPLUS
CN Benzenesulfonamide, 3-[[[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]amino]carbonylamino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-62-5 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl)- (CA INDEX NAME)




RN 606128-52-3 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-54-5 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-56-7 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-64-7 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-66-9 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2,4-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-68-1 CAPLUS
CN Urea, N-[(1S)-3-[(3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-6-quinolinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-70-5 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(4-(methoxymethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-72-7 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-74-9 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-82-9 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorobenzoyl)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(2,5-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-84-1 CAPLUS
CN Benzoic acid, 3-[[[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-86-3 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(methoxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-76-1 CAPLUS
CN Benzamide, 3-[[[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]amino]carbonyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-78-3 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(2,3-dihydro-5-benzofuranyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-80-7 CAPLUS
CN Urea, N-2-benzothiazolyl-N'-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 606128-88-5 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-[4-(methanesulfonyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-90-9 CAPLUS
CN Benzamide, 4-[[[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]amino]carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 606128-92-1 CAPLUS


L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN Acetamide, N-[4-[[[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]amino]carbonyl]amino]phenyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 606128-94-3 CAPLUS
 CN Urea, N-(3-acetylphenyl)-N'-[(1S)-3-[3-(4-chlorobenzoyl)-1-azetidiny]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 606128-96-5 CAPLUS
 CN Urea, N-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(4-fluoro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 606129-04-8 CAPLUS
 CN Urea, N-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-4-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 606129-06-0 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-4-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 606129-08-2 CAPLUS
 CN Urea, N-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2-fluoro-4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 606128-98-7 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-00-4 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(4-fluoro-2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-02-6 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(3-(methylsulfonyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-10-6 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N'-(2-fluoro-4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-13-9 CAPLUS
 CN Urea, N'-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]-N-(3,5-dimethoxyphenyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 606129-17-3 CAPLUS
 CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidiny]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 606129-18-4 CAPLUS
CN Urea, N-[(1S)-3-[3-(3,4-dichlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-19-5 CAPLUS
CN Urea, N-[(1S)-3-[3-(3-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)-3-(3-phenoxy-1-azetidinyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-20-8 CAPLUS
CN Urea, N-[(1S)-3-[3-(3-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-21-9 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenyl)methyl]-1-azetidinyl]propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 606129-22-0 CAPLUS
CN Urea, N-[(1R)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-methylpropyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-23-1 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-3-isoxazolyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-24-2 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3-ethyl-1-(1-methylethyl)-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-25-3 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)-3-(1-isopropyl-1H-pyrazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-26-4 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-[1-(1,1-dimethylethyl)-3-ethyl-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-27-5 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-cycloheptyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 606129-28-6 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-[(1S)-3-[3-(4-fluorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 606129-29-7 CAPLUS
CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)





RN 606129-30-0 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]propyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 606129-31-1 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]propyl]-N'-(5-methyl-3-isoxazolyl)methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 606129-75-3 CAPLUS
 CN Urea, N'-(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-[[[(1,1-dimethylethyl)diphenylsilyloxy)methyl]propyl]-N-(3,5-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


RN 606129-32-2 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 606129-73-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of azetidine derivs. as CCR-3 receptor antagonists)
 RN 606129-73-1 CAPLUS
 CN Urea, N-[(1S)-3-[3-(4-chlorophenoxy)-1-azetidinyl]-1-(hydroxymethyl)propyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 606129-42-4P 606129-75-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azetidine derivs. as CCR-3 receptor antagonists)
 RN 606129-42-4 CAPLUS
 CN Urea, N-(3,5-dimethoxyphenyl)-N'-(1S)-1-[[[(1,1-dimethylethyl)diphenylsilyloxy)methyl]propyl]-3-[3-(4-fluorobenzoyl)-1-azetidinyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

23.06

402.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-3.28

-4.10

STN INTERNATIONAL LOGOFF AT 09:26:32 ON 18 JUN 2009